Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer
A six-marker, multiregional ICP panel delivers a robust, stage-independent, actionable risk stratification in MIBC. At least four biopsies are advised for routine immune profiling; further longitudinal external validation is warranted.
Authors
- Gerald Bastian Schulz (ORCID: https://orcid.org/0000-0002-0340-0304)
- Evelyn Ramberger (ORCID: https://orcid.org/0000-0003-2760-2696)
- Benedikt Ebner (ORCID: https://orcid.org/0000-0003-2126-7305)
- Simon Schallenberg (ORCID: https://orcid.org/0000-0002-7897-7116)
- Frederick Klauschen (ORCID: https://orcid.org/0000-0002-9131-2389)
- Christian Georg Stief (ORCID: https://orcid.org/0000-0003-3291-9460)
- Henning Plage (ORCID: https://orcid.org/0000-0002-7680-1870)
- Gabriel Dernbach
- Dragomir Mihnea-Paul
- Nadia Jurczok
- Guido Sauter
- Florian Roßner
- Marie-Lisa Eich
- Philipp Keyl
- Julika Ribbat-Idel
- Alexander Quaas
- Thorsten Schlomm
- David Horst
Institutions
- Universität Hamburg (DE)
- University of Cologne (DE)
- LMU Klinikum (DE)
- Humboldt-Universität zu Berlin (DE)
- German Cancer Society (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University Hospital Cologne (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.euo.2025.12.006
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01